366 related articles for article (PubMed ID: 27605663)
1. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
[TBL] [Abstract][Full Text] [Related]
2. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
4. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
5. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
6. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
[TBL] [Abstract][Full Text] [Related]
8. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
[TBL] [Abstract][Full Text] [Related]
9. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
10. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
11. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
12. FXR controls CHOP expression in steatohepatitis.
Fuchs CD; Claudel T; Scharnagl H; Stojakovic T; Trauner M
FEBS Lett; 2017 Oct; 591(20):3360-3368. PubMed ID: 28895119
[TBL] [Abstract][Full Text] [Related]
13. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
[TBL] [Abstract][Full Text] [Related]
14. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
15. Trimethylamine N-oxide ameliorates hepatic damage including reduction of hepatic bile acids and cholesterol in
Miyata M; Takeda K; Nagira S; Sugiura Y
Int J Food Sci Nutr; 2024 Jun; 75(4):385-395. PubMed ID: 38690724
[TBL] [Abstract][Full Text] [Related]
16. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
17. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
[TBL] [Abstract][Full Text] [Related]
18. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
19. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
